Niagen Bioscience (NASDAQ:NAGE – Get Free Report) released its quarterly earnings results on Tuesday. The company reported $0.01 EPS for the quarter, hitting the consensus estimate of $0.01, Zacks reports. Niagen Bioscience had a return on equity of 22.68% and a net margin of 14.29%.
Niagen Bioscience Trading Down 1.7%
Shares of NAGE traded down $0.06 during trading hours on Tuesday, reaching $3.47. The company had a trading volume of 1,028,252 shares, compared to its average volume of 979,671. The firm has a 50 day simple moving average of $3.44 and a 200-day simple moving average of $4.39. Niagen Bioscience has a 12-month low of $3.12 and a 12-month high of $11.29. The company has a market capitalization of $276.35 million, a price-to-earnings ratio of 16.52 and a beta of 2.09.
Analyst Upgrades and Downgrades
A number of research firms recently weighed in on NAGE. Wall Street Zen lowered shares of Niagen Bioscience from a “buy” rating to a “hold” rating in a research note on Saturday, April 25th. Canaccord Genuity Group dropped their price objective on shares of Niagen Bioscience from $13.00 to $10.00 and set a “buy” rating on the stock in a research report on Tuesday, May 5th. HC Wainwright reiterated a “buy” rating on shares of Niagen Bioscience in a research note on Wednesday, July 1st. Weiss Ratings reissued a “hold (c)” rating on shares of Niagen Bioscience in a report on Friday, July 17th. Finally, Freedom Capital upgraded shares of Niagen Bioscience to a “strong-buy” rating in a research report on Monday, July 6th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $10.50.
Hedge Funds Weigh In On Niagen Bioscience
Several hedge funds have recently bought and sold shares of NAGE. Ameritas Investment Partners Inc. acquired a new position in shares of Niagen Bioscience in the 3rd quarter valued at $45,000. Quantbot Technologies LP acquired a new stake in shares of Niagen Bioscience during the 3rd quarter worth $48,000. Polymer Capital Management US LLC purchased a new position in shares of Niagen Bioscience in the 3rd quarter worth $96,000. BNP Paribas Financial Markets purchased a new position in shares of Niagen Bioscience in the 3rd quarter worth $96,000. Finally, Brevan Howard Capital Management LP purchased a new position in shares of Niagen Bioscience in the 3rd quarter worth about $96,000. Hedge funds and other institutional investors own 15.41% of the company’s stock.
Niagen Bioscience Company Profile
Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services.
Featured Articles
- Five stocks we like better than Niagen Bioscience
- System Upgrade: First Internet Bancorp Options Surge
- AI Security Breaches Raise New Risks for Microsoft and Amazon’s Agent Push
- The AI Chip Blockade Is Creating a Shadow Market
- Grab Holdings Stock Forms Bottom After Strong Beat-and-Raise Quarter
Receive News & Ratings for Niagen Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Niagen Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
